Four versus Six Cycles of Pemetrexed/Platinum as a First Line Treatment of Malignant Pleural Mesothelima: Results of a Randomized Phase II Study
Nagy, A., Elwakeel, H., Abdel-Rahman, O. (2018). Four versus Six Cycles of Pemetrexed/Platinum as a First Line Treatment of Malignant Pleural Mesothelima: Results of a Randomized Phase II Study. EKB Journal Management System, 14(2), 50-52. doi: 10.21608/resoncol.2018.4306.1062
Ahmed Nagy; Hesham Elwakeel; Omar Abdel-Rahman. "Four versus Six Cycles of Pemetrexed/Platinum as a First Line Treatment of Malignant Pleural Mesothelima: Results of a Randomized Phase II Study". EKB Journal Management System, 14, 2, 2018, 50-52. doi: 10.21608/resoncol.2018.4306.1062
Nagy, A., Elwakeel, H., Abdel-Rahman, O. (2018). 'Four versus Six Cycles of Pemetrexed/Platinum as a First Line Treatment of Malignant Pleural Mesothelima: Results of a Randomized Phase II Study', EKB Journal Management System, 14(2), pp. 50-52. doi: 10.21608/resoncol.2018.4306.1062
Nagy, A., Elwakeel, H., Abdel-Rahman, O. Four versus Six Cycles of Pemetrexed/Platinum as a First Line Treatment of Malignant Pleural Mesothelima: Results of a Randomized Phase II Study. EKB Journal Management System, 2018; 14(2): 50-52. doi: 10.21608/resoncol.2018.4306.1062

Four versus Six Cycles of Pemetrexed/Platinum as a First Line Treatment of Malignant Pleural Mesothelima: Results of a Randomized Phase II Study

Research in Oncology
Article 1, Volume 14, Issue 2, December 2018, Page 50-52  XML PDF (133.63 K)
Document Type: Short communications
DOI: 10.21608/resoncol.2018.4306.1062
View on SCiNiTO View on SCiNiTO
Authors
Ahmed Nagy; Hesham Elwakeel; Omar Abdel-Rahman email
Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
Abstract
Background: Pemetrexed-platinum is the standard first line treatment of patients with malignant pleural mesothelioma (MPM). Optimal number of pemetrexed-platinum chemotherapy cycles is not yet known with certainty.
Aim: To compare 4 cycles versus 6 cycles of pemetrexed-platinum regimen as a 1st line treatment in MPM.
Methods: This was a randomized phase II study (1:1) which was conducted at a single institution. Arm A received 4 cycles of pemetrexed-platinum, while Arm B received 6 cycles. The 1ry outcome of the current study was overall survival. It was assessed through Kaplan-Meier survival estimates as well as a multivariate Cox regression model adjusted for other relevant baseline clinicopathological characteristics.
Results: A total of 60 patients were included into the current study (30 in each arm). Kaplan-Meier survival analysis according to the number of cycles of chemotherapy did not reveal a significant survival difference between both subsets (p = 0.194). Multivariate Cox regression analysis for factors affecting overall survival did not show an overall survival difference based on treatment arm (p = 0.105).
Conclusions: Six cycles does not appear to improve the overall survival of MPM patients compared to four cycles. Shorter course of treatment should be considered in resource-limited settings like Egypt.
Keywords
Malignant Pleural Mesothelioma; 1st line chemotherapy; Pemetrexed
Statistics
Article View: 583
PDF Download: 530